Literature DB >> 34113956

Application of the "immunization islands" model to improve quality, efficiency and safety of a COVID-19 mass vaccination site.

C Signorelli1,2, A Odone2, V Gianfredi1,2, M Capraro1, E Kacerik1, G Chiecca1, A Scardoni1,3, M Minerva1, R Mantecca2, P Musarò2, P Brazzoli3, P Basteri3, B Bertini3, F Esposti2, C Ferri3, V A Alberti3, G Gastaldi4.   

Abstract

Abstract: After SARS-CoV-2 vaccines development came at an unprecedented speed, ensuring safe and efficient mass immunization, vaccine delivery be-came the major public health mandate. Although mass-vaccination sites have been identified as essential to curb COVID-19, their organization and functioning is challenging. In this paper we present the planning, implementation and evalua-tion of a massive vaccination center in Lombardy - the largest Region in Italy and the most heavily hit by the pandemic. The massive hub of Novegro (Milan), managed by the Gruppo Ospedaliero San Donato, opened in April 2021. The Novegro mass-immunization model was developed building a la-yout based on the available scientific evidence, on comparative analysis with other existing models and on the experience of COVID-19 immunization delivery of Gruppo Ospedaliero San Donato. We propose a "vaccine islands" mass-immunization model, where 4 physicians and 2 nurses operate in each island, with up to 10 islands functioning at the same time, with the capacity of providing up to 6,000 vaccinations per day. During the first week of activity a total of 37,900 doses were administered (2,700/day), most of them with Pfizer vaccine (85.8%) and first doses (70.9%). The productivity was 10.5 vaccines/hour/vaccine station. Quality, efficiency and safety were boosted by ad-hoc personnel training, quality technical infrastructure and the presence of a shock room. Constant process monitoring allowed to identify and promptly tackle process pitfalls, including vaccine refusals (0.36%, below expectations) and post-vaccinations adverse reactions (0.4%). Our innovative "vaccine islands" mass-immunization model might be scaled-up or adapted to other settings. The Authors consider that sharing best practices in immunization delivery is fundamen-tal to achieve population health during health emergencies.

Entities:  

Keywords:  COVID-19; Mass immunization centers; adverse effects; vaccination

Year:  2021        PMID: 34113956     DOI: 10.7416/ai.2021.2456

Source DB:  PubMed          Journal:  Ann Ig        ISSN: 1120-9135


  6 in total

1.  Applying Lean principles to create a high throughput mass COVID-19 vaccination site.

Authors:  Meghan N Froman; Matthew P Walser; Michael Lauzardo; Mark Graban; Frederick S Southwick
Journal:  BMJ Open Qual       Date:  2022-02

2.  Immediate adverse events following COVID-19 immunization. A cross-sectional study of 314,664 Italian subjects.

Authors:  Vincenza Gianfredi; Massimo Minerva; Giulia Casu; Michele Capraro; Greta Chiecca; Giovanni Gaetti; Rosaria Mantecca Mazzocchi; Patrizia Musarò; Pasquale Berardinelli; Paola Basteri; Beatrice Bertini; Camilla Ferri; Anna Odone; Carlo Signorelli; Valerio Fabio Alberti; Gilda Gastaldi
Journal:  Acta Biomed       Date:  2021-10-19

Review 3.  Addressing vaccine hesitancy and resistance for COVID-19 vaccines.

Authors:  Micah D J Peters
Journal:  Int J Nurs Stud       Date:  2022-04-01       Impact factor: 6.612

4.  Covid-19 Massive Vaccination Center Layouts.

Authors:  Andrea Brambilla; Silvia Mangili; Marco Macchi; Paolo Trucco; Alessandro Perego; Stefano Capolongo
Journal:  Acta Biomed       Date:  2021-10-05

5.  HPV Vaccination during the COVID-19 Pandemic in Italy: Opportunity Loss or Incremental Cost.

Authors:  Francesco Saverio Mennini; Andrea Silenzi; Andrea Marcellusi; Michele Conversano; Andrea Siddu; Giovanni Rezza
Journal:  Vaccines (Basel)       Date:  2022-07-16

Review 6.  Challenges and Opportunities of Mass Vaccination Centers in COVID-19 Times: A Rapid Review of Literature.

Authors:  Vincenza Gianfredi; Flavia Pennisi; Alessandra Lume; Giovanni Emanuele Ricciardi; Massimo Minerva; Matteo Riccò; Anna Odone; Carlo Signorelli
Journal:  Vaccines (Basel)       Date:  2021-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.